Lung cancer multi-omics digital human avatars for integrating precision medicine into clinical practice: the LANTERN study.
Artificial intelligence (AI)
Big data
Digital human avatars (DHA)
Genomics
Lung cancer
Machine learning
Personalize medicine
Precision medicine
Radiomics
System medicine
Journal
BMC cancer
ISSN: 1471-2407
Titre abrégé: BMC Cancer
Pays: England
ID NLM: 100967800
Informations de publication
Date de publication:
13 Jun 2023
13 Jun 2023
Historique:
received:
17
04
2023
accepted:
22
05
2023
medline:
15
6
2023
pubmed:
14
6
2023
entrez:
13
6
2023
Statut:
epublish
Résumé
The current management of lung cancer patients has reached a high level of complexity. Indeed, besides the traditional clinical variables (e.g., age, sex, TNM stage), new omics data have recently been introduced in clinical practice, thereby making more complex the decision-making process. With the advent of Artificial intelligence (AI) techniques, various omics datasets may be used to create more accurate predictive models paving the way for a better care in lung cancer patients. The LANTERN study is a multi-center observational clinical trial involving a multidisciplinary consortium of five institutions from different European countries. The aim of this trial is to develop accurate several predictive models for lung cancer patients, through the creation of Digital Human Avatars (DHA), defined as digital representations of patients using various omics-based variables and integrating well-established clinical factors with genomic data, quantitative imaging data etc. A total of 600 lung cancer patients will be prospectively enrolled by the recruiting centers and multi-omics data will be collected. Data will then be modelled and parameterized in an experimental context of cutting-edge big data analysis. All data variables will be recorded according to a shared common ontology based on variable-specific domains in order to enhance their direct actionability. An exploratory analysis will then initiate the biomarker identification process. The second phase of the project will focus on creating multiple multivariate models trained though advanced machine learning (ML) and AI techniques for the specific areas of interest. Finally, the developed models will be validated in order to test their robustness, transferability and generalizability, leading to the development of the DHA. All the potential clinical and scientific stakeholders will be involved in the DHA development process. The main goals aim of LANTERN project are: i) To develop predictive models for lung cancer diagnosis and histological characterization; (ii) to set up personalized predictive models for individual-specific treatments; iii) to enable feedback data loops for preventive healthcare strategies and quality of life management. The LANTERN project will develop a predictive platform based on integration of multi-omics data. This will enhance the generation of important and valuable information assets, in order to identify new biomarkers that can be used for early detection, improved tumor diagnosis and personalization of treatment protocols. 5420 - 0002485/23 from Fondazione Policlinico Universitario Agostino Gemelli IRCCS - Università Cattolica del Sacro Cuore Ethics Committee. clinicaltrial.gov - NCT05802771.
Sections du résumé
BACKGROUND
BACKGROUND
The current management of lung cancer patients has reached a high level of complexity. Indeed, besides the traditional clinical variables (e.g., age, sex, TNM stage), new omics data have recently been introduced in clinical practice, thereby making more complex the decision-making process. With the advent of Artificial intelligence (AI) techniques, various omics datasets may be used to create more accurate predictive models paving the way for a better care in lung cancer patients.
METHODS
METHODS
The LANTERN study is a multi-center observational clinical trial involving a multidisciplinary consortium of five institutions from different European countries. The aim of this trial is to develop accurate several predictive models for lung cancer patients, through the creation of Digital Human Avatars (DHA), defined as digital representations of patients using various omics-based variables and integrating well-established clinical factors with genomic data, quantitative imaging data etc. A total of 600 lung cancer patients will be prospectively enrolled by the recruiting centers and multi-omics data will be collected. Data will then be modelled and parameterized in an experimental context of cutting-edge big data analysis. All data variables will be recorded according to a shared common ontology based on variable-specific domains in order to enhance their direct actionability. An exploratory analysis will then initiate the biomarker identification process. The second phase of the project will focus on creating multiple multivariate models trained though advanced machine learning (ML) and AI techniques for the specific areas of interest. Finally, the developed models will be validated in order to test their robustness, transferability and generalizability, leading to the development of the DHA. All the potential clinical and scientific stakeholders will be involved in the DHA development process. The main goals aim of LANTERN project are: i) To develop predictive models for lung cancer diagnosis and histological characterization; (ii) to set up personalized predictive models for individual-specific treatments; iii) to enable feedback data loops for preventive healthcare strategies and quality of life management.
DISCUSSION
CONCLUSIONS
The LANTERN project will develop a predictive platform based on integration of multi-omics data. This will enhance the generation of important and valuable information assets, in order to identify new biomarkers that can be used for early detection, improved tumor diagnosis and personalization of treatment protocols.
ETHICS COMMITTEE APPROVAL NUMBER
UNASSIGNED
5420 - 0002485/23 from Fondazione Policlinico Universitario Agostino Gemelli IRCCS - Università Cattolica del Sacro Cuore Ethics Committee.
TRIAL REGISTRATION
BACKGROUND
clinicaltrial.gov - NCT05802771.
Identifiants
pubmed: 37312079
doi: 10.1186/s12885-023-10997-x
pii: 10.1186/s12885-023-10997-x
pmc: PMC10262371
doi:
Banques de données
ClinicalTrials.gov
['NCT05802771']
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
540Commentaires et corrections
Type : ErratumIn
Informations de copyright
© 2023. The Author(s).
Références
Anticancer Res. 2018 Apr;38(4):2155-2160
pubmed: 29599334
Int J Med Sci. 2013;10(3):320-30
pubmed: 23423768
Radiology. 2020 May;295(2):328-338
pubmed: 32154773
Annu Int Conf IEEE Eng Med Biol Soc. 2015 Aug;2015:771-4
pubmed: 26736376
Curr Pharm Des. 2014;20(38):5945-56
pubmed: 24641232
Sci Rep. 2018 Feb 19;8(1):3284
pubmed: 29459639
J Med Syst. 2020 Aug 4;44(9):161
pubmed: 32748066
Nat Biotechnol. 2018 Nov 9;36(11):1053-1055
pubmed: 30412185
Eur Urol. 2015 Jun;67(6):1142-1151
pubmed: 25572824
J Pers Med. 2022 Oct 20;12(10):
pubmed: 36294885
Int J Med Inform. 2017 Dec;108:1-8
pubmed: 29132615
Radiat Oncol. 2017 Sep 15;12(1):154
pubmed: 28915902
Sci Rep. 2016 Sep 20;6:33860
pubmed: 27645803
Genome Med. 2019 Dec 31;12(1):4
pubmed: 31892363
Nat Rev Clin Oncol. 2020 Dec;17(12):771-781
pubmed: 32843739
Acad Radiol. 2018 Dec;25(12):1548-1555
pubmed: 29572049
Oncotarget. 2017 Nov 01;8(61):104393-104407
pubmed: 29262648
Front Oncol. 2019 Oct 01;9:977
pubmed: 31632910